Artesunate

Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.3. Antimalarial medicines > 6.5.3.1. Antimalarial medicines > Medicines for curative treatment

EMLc ATC codes: P01BE03

Indication	Malaria due to Plasmodium vivax ICD11 code: 1F41
INN	Artesunate
Medicine type	Chemical agent
List type	Core
Additional notes	For use in the management of severe malaria
Formulations	**Parenteral > General injections > IV:** 60 mg in vial powder for injection ; 30 mg in vial powder for injection ; 120 mg in vial powder for injection **Local > Rectal > Other:** 100 mg capsules (EMLc)
EML status history	First added in 1999 (TRS 895) Changed in 2002 (TRS 914) Changed in 2007 (TRS 946) Changed in 2007 (TRS 950) Changed in 2017 (TRS 1006) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Artesunate
DrugBank	Artesunate

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of artesunate powder for injection 30 mg, 60 mg and 120 mg on the EML and EMLc; - the deletion of the previously listed injection formulation of artesunate from the EML and EMLc; - the deletion of 50 mg and 200 mg artesunate rectal capsules from the EML and EMLc; - the deletion of 50 mg artesunate tablets from the EML and EMLc. - the removal of footnotes regarding follow-up care and combination use.